Tower Research Capital (TRC)’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-7,813
| Closed | -$158K | – | 7001 |
|
|
2021
Q3 | $158K | Buy |
7,813
+4,161
| +114% | +$115K | ﹤0.01% | 2029 |
|
|
2021
Q2 | $136K | Buy |
3,652
+238
| +7% | +$7.29K | ﹤0.01% | 2182 |
|
|
2021
Q1 | $87K | Sell |
3,414
-4,991
| -59% | -$127K | ﹤0.01% | 2698 |
|
|
2020
Q4 | $185K | Buy |
8,405
+5,100
| +154% | +$112K | 0.01% | 1774 |
|
|
2020
Q3 | $59K | Sell |
3,305
-11,922
| -78% | -$247K | ﹤0.01% | 3472 |
|
|
2020
Q2 | $387K | Buy |
+15,227
| New | +$328K | 0.02% | 1236 |
|
|
2020
Q1 | – | Sell |
-8,018
| Closed | -$177K | – | 4280 |
|
|
2019
Q4 | $177K | Buy |
8,018
+7,618
| +1,905% | +$153K | 0.01% | 640 |
|
|
2019
Q3 | $6K | Buy |
+400
| New | +$5.72K | ﹤0.01% | 3271 |
|
|
2019
Q2 | – | Sell |
-2,569
| Closed | -$37K | – | 4574 |
|
|
2019
Q1 | $37K | Buy |
+2,569
| New | +$29.5K | ﹤0.01% | 1928 |
|
|
2018
Q4 | – | Sell |
-532
| Closed | -$8K | – | 4572 |
|
|
2018
Q3 | $8K | Sell |
532
-265
| -33% | -$3.86K | ﹤0.01% | 2923 |
|
|
2018
Q2 | $10K | Sell |
797
-739
| -48% | -$9.28K | ﹤0.01% | 2805 |
|
|
2018
Q1 | $15K | Sell |
1,536
-9,024
| -85% | -$97.3K | ﹤0.01% | 2320 |
|
|
2017
Q4 | $95K | Buy |
+10,560
| New | +$77.7K | 0.01% | 900 |
|
|
2017
Q2 | – | Sell |
-4,575
| Closed | -$16K | – | 3708 |
|
|
2017
Q1 | $16K | Sell |
4,575
-1,562
| -25% | -$4.4K | ﹤0.01% | 1458 |
|
|
2016
Q4 | $18K | Buy |
+6,137
| New | +$21.8K | ﹤0.01% | 2255 |
|
|
2016
Q3 | – | Sell |
-1,220
| Closed | -$4K | – | 4764 |
|
|
2016
Q2 | $4K | Sell |
1,220
-12
| -1% | -$49 | ﹤0.01% | 3587 |
|
|
2016
Q1 | $7K | Sell |
1,232
-2,935
| -70% | -$18.5K | ﹤0.01% | 2435 |
|
|
2015
Q4 | $49K | Buy |
+4,167
| New | +$47.7K | 0.01% | 574 |
|
|
2015
Q3 | – | Sell |
-887
| Closed | -$12K | – | 5051 |
|
|
2015
Q2 | $12K | Sell |
887
-321
| -27% | -$5.89K | ﹤0.01% | 2561 |
|
|
2015
Q1 | $29K | Buy |
1,208
+383
| +46% | +$8.61K | ﹤0.01% | 1950 |
|
|
2014
Q4 | $14K | Buy |
+825
| New | +$9.52K | ﹤0.01% | 1867 |
|
|
2014
Q3 | – | Sell |
-10
| Closed | – | – | 5050 |
|
|
2014
Q2 | $0 | Buy |
+10
| New | +$181 | ﹤0.01% | 4832 |
|
Other funds holding DRNA
Tower Research Capital (TRC)'s DRNA Position: Q4 2021 in Review
Tower Research Capital (TRC) sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 7,813 shares — an estimated $158K sold.
Tower Research Capital (TRC) first reported a position in DRNA in Q2 2014 and held it in 22 quarters. The position peaked at $387K in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Tower Research Capital (TRC) reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 7,813 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $158K.
- Tower Research Capital (TRC) first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 22 quarters.
- Tower Research Capital (TRC)'s Dicerna Pharmaceuticals, Inc. position peaked at $387K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2021, filed 14 Feb 2022.